Pfizer/Astellas Take Off On New Xtandi Expansion With EMBARK Data
Astellas Has Said This Kind Of Trial Could Be More Challenging Under IRA
Data from the Phase III EMBARK study showed a significant improvement for the drug both in combination with leuprolide and as a monotherapy in reducing risk of metastasis or death in nmHSPC.
